Respiratory Syncytial Virus Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

• There will be 20,901,943 diagnosed seropositive prevalent cases of RSV across the 8MM in 2023.
• Currently, there are only three marketed drugs for RSV: two monoclonal antibodies (palivizumab and nirsevimab) and one antiviral drug (ribavirin).
• R&D activity within the RSV space is significant, with 10 pipeline products in late-stage clinical development.
• Commercial sponsors currently dominate the RSV clinical development space, with the US, Spain, and Australia emerging as key countries for conducting Phase III trials in RSV.
• Three licensing agreements, one acquisition deal, and two partnerships were implemented among companies developing RSV assets in the past 12 months.

Scope

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the RSV market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RSV market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.